Phase Resetting in Medicine and Biology: Stochastic Modelling and Data Analysis (Springer Series in Synergetics)

Phase Resetting in Medicine and Biology: Stochastic Modelling and Data Analysis (Springer Series in Synergetics)

The book presents a new theoretical approach to phase resetting and stimulation-induced synchronization and desynchronization in a population of oscillators. The author uses stochastic methods from statistical mechanics and applies his theory to models of practical importance in physiology and neuroscience. He makes the book accessible to readers not familiar with the mathematical formalism. The results are presented and additionally explained without formulae, particularly with a view to the interests of neuroscientists. The author also proposes improvements to stimulation techniques as used by neurologists and neurosurgeons in the context of Parkinson’s disease and MEG/EEG data analysis. The book is written for researchers and graduate students but it can also benefit medical practitioners.

List Price: $ 69.95

Price: $ 41.07

Synchronization in Oscillatory Networks (Springer Series in Synergetics)

This work systematically investigates a large number of oscillatory network configurations that are able to describe many real systems such as electric power grids, lasers or even the heart muscle, to name but a few. The book is conceived as an introduction to the field for graduate students in physics and applied mathematics as well as being a compendium for researchers from any field of application interested in quantitative models.

List Price: $ 109.00

Price: $ 87.00

First Patients Recruited In The Extended Phase III Programme Using Lu AA21004 In MDD

First Patients Recruited In The Extended Phase III Programme Using Lu AA21004 In MDD
H. Lundbeck A/S (Lundbeck) announced that the first patients have been recruited and dosed in the new phase III programme using Lu AA21004 in major depression (MDD). The first patients have been recruited in Finland. As previously communicated filing of Lu AA21004 is anticipated in 2012. The extended phase III programme for Lu AA21004 is based on clinical data obtained until now…

Read more on Medical News Today

Pre-clinical to Phase IV Urology Research & Development Partnership Developed

Pre-clinical to Phase IV Urology Research & Development Partnership Developed
The first Urology-focused partnership with deep expertise in pre-clinical to Phase IV contract research.

Read more on PRWeb via Yahoo! News

Pro-Pharmaceuticals plans to submit Phase III trial design for DAVANAT to FDA

Pro-Pharmaceuticals plans to submit Phase III trial design for DAVANAT to FDA
Pro-Pharmaceuticals, Inc., the leading developer of therapeutics that target Galectin receptors to treat cancer and fibrosis, today announced plans to submit a Phase III trial design for DAVANAT to the U.S. Food and Drug Administration during the second half of 2010. The Company has added the talent of Peter G. Traber, M.D., to its FDA approval strategy and trial design team.

Read more on News-Medical-Net

Data from three Phase II clinical trials of PS-targeting antibody to be presented at 2010 ASCO Annual Meeting

Data from three Phase II clinical trials of PS-targeting antibody to be presented at 2010 ASCO Annual Meeting
Peregrine Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing innovative monoclonal antibodies for the treatment of cancer and viral infections, will present data from three Phase II clinical trials highlighting the clinical potential of its unique phosphatidylserine -targeting antibody bavituximab for the treatment of solid tumors.

Read more on News-Medical-Net

Next Page »